Quanome Technologies, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
QNME$0.34+5.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
CONDENSSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND 2024
| For the Nine Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(4,353,023) | $(230,293) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Depreciation – G&A | 86,413 | 53,985 |
| Depreciation – cost of revenue | 62,441 | 54,493 |
| Amortization of intangible asset | 32,056 | — |
| Amortization and interest expense of operating lease assets | 1,515,688 | 658,713 |
| Depreciation of right-of-use finance assets | 24,081 | 22,548 |
| Provision of allowance for expected credit loss | 8,021 | 22,198 |
| Interest expense of convertible note | 40,541 | — |
| Deferred tax expense | 81,567 | 36,264 |
| Interest income | (11,645) | — |
| Loss from derecognition of shares in subsidiary | — | 73,151 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable – third parties | 666,858 | (283,936) |
| Accounts receivable – related parties | 466,764 | (565,824) |
| Contract assets | 58,175 | (58,498) |
| Inventories, net | (216,489) | — |
| Due from related parties | (41,230) | 212,342 |
| Due to related party | — | 14,536 |
| Prepayment and other deposit | (158,359) | 2,623 |
| Accounts payables – third parties | 415,186 | 493,085 |
| Accounts payables – related parties | (158,827) | 57,420 |
| Contract liabilities | 42,168 | — |
| Accrued expense and other payables | 393,633 | 111,122 |
| Tax payable | 26,608 | 94,471 |
| Operating lease liabilities | (1,151,931) | (606,756) |
| Net cash (used in) provided by operating activities | (2,171,304) | 161,644 |
| Cash flows from investing activities: | ||
| Purchase of furniture and equipment | (36,072) | — |
| Payment for leasehold improvement | (76,456) | — |
| Net cash payment for asset acquisition | (552,721) | — |
| Loan to a third party | (561,901) | — |
| Payment made for investment in other entity | — | (29,906) |
| Net cash outflow from deconsolidation of a subsidiary (Appendix A) | — | (48,893) |
| Net cash used in investing activities | (1,227,150) | (78,799) |
| Cash flows from financing activities: | ||
| Proceeds from loans | 294,975 | 225,000 |
| Repayment of loans | (420,765) | (200,132) |
| Net proceeds from issuance of convertible notes | 755,512 | — |
| Proceeds from a loan from a related party | 124,176 | — |
| Repayment of equipment and vehicle loans | (85,591) | (89,802) |
| Principal payment of finance lease liabilities | (22,814) | (21,485) |
| Payment for deferring offering cost | — | (140,000) |
| Advances from Hupan Pharmaceutical prior to acquisition | 276,365 | — |
| Proceeds from initial public offering, net of share issuance costs | 5,351,281 | — |
| Advances to related parties | (685,247) | — |
| Proceeds from shareholders | — | 158,455 |
| Repayment to shareholders | (805,345) | — |
| Net cash provided by (used in) financing activities | 4,782,547 | (67,964) |
| Effect of exchange rate changes on cash | (8,386) | 3,216 |
| Net increase in cash | 1,375,707 | 18,097 |
| Cash, beginning of the period | 123,550 | 174,018 |
| Cash, end of the period | $1,499,257 | $192,115 |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||
| Cash paid for income tax | $— | $— |
| Cash paid for interest | $67,704 | $24,030 |
| SUPPLEMENTAL SCHEDULE OF NON-CASH IN INVESTING AND FINANCING ACTIVITIES | ||
| Deferred offering costs within due to shareholders | $— | $660,826 |
| Deferred offering costs within accrued expense and other payables | $— | $176,176 |
| Property additions included in loan payable | $102,235 | — |
| Additions to leasehold improvement through accounts payable and other payable | $123,176 | — |
| Due to shareholder offset against due from related parties | $311,185 | — |
| NON-CASH ACTIVITIES | ||
| Right of use assets obtained in exchange for operating lease obligations | $1,447,494 | $— |
| Right of use assets obtained in exchange for finance lease obligation | $89,003 | $19,982 |
| APPENDIX A – Net cash outflow from deconsolidation of a subsidiary | ||
| Working capital, net | $29,812 | |
| Investment in other entity recognized | (15,741) | |
| Elimination of NCl at deconsolidation of a subsidiary | 10,187 | |
| Loss from deconsolidation of a subsidiary | (73,151) | |
| Cash | $(48,893) | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.